Combinations of Bevacizumab, thalidomide, docetaxel and prednisone offer benefits to patients with metastatic prostate cancer, which had no impact on kastrasi. This was presented by researcher Dr. Ning and colleagues as their phase II study, published in Journal of Clinical Oncology in April 2010.
The objective of previous studies showed that thalidomide provides additional activity against docetaxel in patients with metastatic prostate cancer who had no impact on kastrasi or Castration-resistant prostate cancer (CRPC). Where a phase II study combining docetaxel with bevacizumab has the effect of antitumor activity. Researchers hypothesize combining docetaxel plus drugs have different targets antiangiogenik with clinical activity of the more useful of course. To get the safety and efficacy, research on guinea pig to experiment on rats and humans.
Using the preclinical effectiveness of the treatment combination were evaluated in mice that carried PC3 xenograft transplantation. A total of 60 patient with metastatic cancer who had no impact postat with kastrasi or CRPC received a combination of bevacizumab plus docetaxel and thalidomide and prednisone in peroral. As a primary end goal is the reduction of Prostate-specific antigen values (PSA) of greater or equal to 50%. As a result of secondary objectives include the Time to progression, Overall survival, and security.
Results in animal models try with docetaxel combination treatment, bevacizumab, and thalidomide inhibits tumor growth effectively. Whereas in clinical studies, as many as 90% of patients who received the combination treatment PSAnya value decreased by 50% or more, and approximately 88% of patients experienced a decrease of PSA value by 30% or more within the first 3 months of treatment. As the median time to progression was 18.3 months and median overall survival was 28.2 months in this group with-Halabi Predicted survival was 14 months. The toxicity can still be rectified and all patients experienced neutropenia grade 3 / 4.
The conclusion of this phase II study with the regimens / combinations doxetacel, bevacizumab and thalidomide, have high activity with toxicity of treatment that can be tackled. The definitive results of experiments that combine with one antiangiogenik agent docetaxel can improve treatment outcomes in patients with metastatic prostate cancer who had no impact kastrasi or metastatic CRPC.
The objective of previous studies showed that thalidomide provides additional activity against docetaxel in patients with metastatic prostate cancer who had no impact on kastrasi or Castration-resistant prostate cancer (CRPC). Where a phase II study combining docetaxel with bevacizumab has the effect of antitumor activity. Researchers hypothesize combining docetaxel plus drugs have different targets antiangiogenik with clinical activity of the more useful of course. To get the safety and efficacy, research on guinea pig to experiment on rats and humans.
Using the preclinical effectiveness of the treatment combination were evaluated in mice that carried PC3 xenograft transplantation. A total of 60 patient with metastatic cancer who had no impact postat with kastrasi or CRPC received a combination of bevacizumab plus docetaxel and thalidomide and prednisone in peroral. As a primary end goal is the reduction of Prostate-specific antigen values (PSA) of greater or equal to 50%. As a result of secondary objectives include the Time to progression, Overall survival, and security.
Results in animal models try with docetaxel combination treatment, bevacizumab, and thalidomide inhibits tumor growth effectively. Whereas in clinical studies, as many as 90% of patients who received the combination treatment PSAnya value decreased by 50% or more, and approximately 88% of patients experienced a decrease of PSA value by 30% or more within the first 3 months of treatment. As the median time to progression was 18.3 months and median overall survival was 28.2 months in this group with-Halabi Predicted survival was 14 months. The toxicity can still be rectified and all patients experienced neutropenia grade 3 / 4.
The conclusion of this phase II study with the regimens / combinations doxetacel, bevacizumab and thalidomide, have high activity with toxicity of treatment that can be tackled. The definitive results of experiments that combine with one antiangiogenik agent docetaxel can improve treatment outcomes in patients with metastatic prostate cancer who had no impact kastrasi or metastatic CRPC.
0 comments:
Post a Comment